132
Participants
Start Date
November 15, 2024
Primary Completion Date
October 15, 2027
Study Completion Date
April 15, 2028
OMNi-BiOTiC® 41167
The probiotic OMNi-BiOTiC® 41167 consists of 3g of 3 x 10\^9 CFU total L. gasseri W15, L. plantarum W1, L. plantarum W21, B. lactis W51, L. acidophilus W70 and L. reuteri W192 per sachet of which two are to be taken each day. Additional non-probiotic components are cranberry-extract (0.01g), D-mannose (0,4 g), vitamin D (2,25µg), maize starch and hydrolyzed rice protein. All the strains in OMNi-BiOTiC® 41167 are specifically tested and selected for their inhibition potential against the known most common uropathogens like the uropathogenic Escherichia coli (UPEC), Klebsiella pneumonia, Proteus mirabilis and Entercoccus faecalis.
Placebo
The placebo consists of all components of OMNi-BiOTiC® 41167, except the probiotic bacteria, cranberry-extract, D-mannose and vitamin D. It has the same smell, taste and texture as the OMNi-BiOTiC® 41167.
Presidio Ospedaliero Universitario S. Maria della Misericordia, ASUFC, Udine
Collaborators (1)
Winclove Probiotics B.V.
INDUSTRY
Institut AllergoSan
UNKNOWN
University Hospital, Udine, Italy
OTHER